Karyopharm holders report small stakes in common stock

Karyopharm Therapeutics Inc. ownership update: three affiliated Millennium entities and Israel A. Englander report shared beneficial interests in common stock as of 03/31/2026.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. ownership update: three affiliated Millennium entities and Israel A. Englander report shared beneficial interests in common stock as of 03/31/2026. Integrated Core Strategies (US) LLC reports 423,982 shares (1.9%); Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 511,571 shares (2.3%). The filing states these holdings are subject to shared voting and dispositive power and includes a joint filing agreement dated April 10, 2026.

Insights

Investor Relations / Governance Analyst

Routine ownership disclosure by affiliated investment managers and principal.

The Schedule 13G/A lists shared voting and dispositive power for listed Millennium entities and Israel A. Englander over specified share amounts: 423,982 shares and 511,571 shares, with reported percentages of 1.9% and 2.3% respectively as of 03/31/2026. The filing reflects joint reporting rather than a change-of-control assertion.

Cash‑flow treatment and intent (passive vs active investment) are not stated; the joint filing agreement dated April 10, 2026 governs coordinated disclosure. Subsequent filings would show material changes to these positions.

Key Figures

Reporting date: 03/31/2026 Integrated Core Strategies (US) LLC holdings: 423,982 shares Millennium / Englander holdings: 511,571 shares +1 more

4 metrics

Reporting date 03/31/2026 cover page reporting date

Integrated Core Strategies (US) LLC holdings 423,982 shares reported shared voting/dispositive power, <date>03/31/2026</date>

Millennium / Englander holdings 511,571 shares each reported with shared voting/dispositive power, <date>03/31/2026</date>

Reported ownership percentages 1.9% and 2.3% percent of class shown on cover pages

Key Terms

Schedule 13G/A, Shared Voting Power, Joint Filing Agreement

3 terms

Schedule 13G/A regulatory

"Amendment No. 1 ) Karyopharm Therapeutics Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Shared Voting Power financial

"Shared Voting Power 423,982.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

Joint Filing Agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of April 10, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Integrated Core Strategies (US) LLC report in KPTI?

Integrated Core Strategies (US) LLC reports 423,982 shares, representing 1.9% of Karyopharm common stock as of 03/31/2026. The filing shows shared voting and dispositive power over these shares.

How many shares do Millennium entities and Israel A. Englander report in KPTI?

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 511,571 shares, equal to 2.3% of the class as of 03/31/2026. The holdings are reported with shared voting and dispositive power.

What form was filed to report these holdings for KPTI?

A Schedule 13G/A amendment was filed to disclose beneficial ownership for Karyopharm common stock, with reporting parties filing a joint filing agreement dated April 10, 2026.

Does the filing state whether these holders control Karyopharm?

No. The filing explains holdings are subject to voting control and investment discretion by Millennium managers but explicitly notes this should not be construed as an admission of beneficial ownership or control.

What is the reporting date for the KPTI share counts?

The share counts are presented with an effective date of 03/31/2026 on the cover pages, and signatures on the amendment are dated April 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 05:28 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

48576U205

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 423,982.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 423,982.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

423,982.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 511,571.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 511,571.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

511,571.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 511,571.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 511,571.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

511,571.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 48576U205

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 511,571.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 511,571.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

511,571.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Karyopharm Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/10/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/10/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/10/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	04/10/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of April 10, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.